-
Mashup Score: 0Diabetes Dialogue: Oral GLP-1 Orforglipron in ACHIEVE-1 Trial - 33 minute(s) ago
In this episode, hosts explore promising results of orforglipron, a new oral GLP-1 receptor agonist, showing significant A1C reduction and weight loss potential.
Source: www.hcplive.comCategories: General Medicine NewsTweet
-
Mashup Score: 0Non-Skimmed Milk Consumption Linked to Increased MAFLD Risk - 6 hour(s) ago
Findings suggest frequent consumption of non-skimmed milk may heighten the risk of developing MAFLD.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
Does the type of milk you drink affect your risk of #liver disease? New research says it might. The analysis of NHANES data found frequent consumption of non-skimmed milk is linked to an increased risk of developing MAFLD. Learn more: https://t.co/XUA3MIpBlz
-
-
Mashup Score: 0
In this analysis, investigators compared older and younger patients with psoriasis in terms of drug survival and other results of biologic medications.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
Biologic treatment efficacy for #psoriasis is comparable between older and younger patients, new data suggest, although drug survival rates among older patients are lower in the treatment period. View our summary here... https://t.co/msm7l1hxkW #dermatology
-
-
Mashup Score: 1
HCPLive is a clinical news and information portal, offering physicians specialty and disease-specific resources, conference coverage, and interviews.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
A new survey reveals confusion among rheumatologists over which toe joints to include in the PsA 66/68 count. Read more about the survey here: https://t.co/sc0w3OpxGv
-
-
Mashup Score: 0Clinical Perspectives in IBD: An IL-23 Inhibitor with Head-to-Head Results in an Open-Label Crohn’s Disease Study - GI Therapies HCP Live - 11 hour(s) ago
Evaluate efficacy and show safety results of Risankizumab vs Ustekinumab for the treatment of moderate-to-severe Crohn’s Disease. Explore the study design and outcomes of Risankizumab’s Phase 3 Crohn’s Disease Program, showing its efficacy across symptomatic and objective endpoints.
Source: gi-therapies.hcplive.comCategories: General Medicine NewsTweet-
Check out our iPub® Clinical Perspectives in IBD: An IL-23 Inhibitor with Head-to-Head Results in an Open-Label Crohn’s Disease Study. Parambir S. Dulai, MD will explore the IL-23 inhibitor’s efficacy in Crohn’s Disease trials. Watch now. https://t.co/IDf5JQ0ckH https://t.co/xmk8s9K1CQ
-
-
Mashup Score: 0Intro and CATALYST Overview - 11 hour(s) ago
Watch expert panelists share perspectives on real patient cases to help fellow clinicians better understand and recognize hypercortisolism. Watch expert panelists share perspectives on real patient cases to help fellow clinicians better understand and recognize hypercortisolism. Elevate awareness of hypercortisolism among endocrinologists, diabetologists, and primary care physicians Elevate awareness of hypercortisolism among endocrinologists, diabetologists, and primary care physicians. Empower HCPs to
Source: www.hcplive.comCategories: General Medicine NewsTweet-
Don’t miss the On-Demand Presentation From Puzzle to Progress: Piecing Together Hypercortisolism. Our panel of healthcare experts will share strategies for recognizing hypercortisolism and offer valuable insights. Watch Now. https://t.co/T95x1BfpDw https://t.co/ggTdayoBia
-
-
Mashup Score: 1
These phase 2a data on IMG-007, a nondepleting anti-OX40 monoclonal antibody, highlight its efficacy among those with alopecia areata.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
🚨NEW🚨 In new topline data, IMG-007, targeting OX40, showed dose-related hair regrowth and SALT score improvements in severe #alopecia areata patients. Want to learn more?🤔 View here: https://t.co/UyilfoIbfm
-
-
Mashup Score: 1Largest Osteoarthritis GWAS to Date Highlights Opportunities for Drug Repurposing and Novel Targets - 12 hour(s) ago
Ten percent of effector genes identified express proteins targeted by approved drugs across disease fields.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
A new GWAS identified 700 effector genes for #osteoarthritis, with 10% linked to proteins targeted by approved drugs, offering new drug targets and repurposing opportunities. Read more: https://t.co/b2HoUEU7BX
-
-
Mashup Score: 1
Real-world data show omalizumab, alone or with OIT, is effective and well-tolerated for IgE-mediated food allergy, with high response rates in adults.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
A real-world study across Europe found 83.9% of patients responded to #omalizumab with or without oral immunotherapy for IgE-mediated food allergy. Read more this data here: https://t.co/CtvWOuWdJH
-
-
Mashup Score: 0Study Identifies Risk Factors Linked to Excessive Sun Exposure in Those with Psoriasis - 17 hour(s) ago
These data highlight the risk level among certain patients with psoriasis of excessive sun exposure, associated commonly with tanning.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
In #dermatology news: New findings suggest excessive sun exposure (ESE) among patients with #psoriasis is more likely among patients who are female, younger, of average weight, of intermediate skin phenotype, and who have a history of phototherapy. https://t.co/m3T9v8wQn3
-
In the latest #DiabetesDialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the topline results from the ACHIEVE-1 trial evaluating oral orforglipron for adults with type 2 diabetes inadequately controlled by diet and exercise. đź”—https://t.co/8N47k0w7qd #Diabetes https://t.co/Pq2lpLtbq1